High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation

Pathogens and Disease

Volumn 70, Issue 3, 2014, Pages 423-431

  Pierce, Christopher G ^a   Saville, Stephen P ^a   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Biofilms; Candida albicans; Chemical library; Filamentation; High content screening

Indexed keywords

ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; FUNGAL GENETICS; GENOMICS; HOSPITAL INFECTION; HUMAN; HUMAN CELL; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SCREENING; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GROWTH, DEVELOPMENT AND AGING; HIGH THROUGHPUT SCREENING; MICROBIAL SENSITIVITY TEST; MOLECULAR LIBRARY; PHYSIOLOGY; PROCEDURES;

ANTIFUNGAL AGENT; MOLECULAR LIBRARY;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; SMALL MOLECULE LIBRARIES;

EID: 84921263121     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12161     Document Type: Article

References (40)

1. Bachmann SP, Patterson TF & Lopez-Ribot JL (2002) In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40: 2228-2230.
2. Baillie GS & Douglas LJ (1999) Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 48: 671-679.
3. Bastidas RJ, Heitman J & Cardenas ME (2009) The protein kinase Tor1 regulates adhesin gene expression in Candida albicans. PLoS Pathog 5: e1000294.
4. Berman J & Sudbery PE (2002) Candida albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genet 3: 918-930.
5. Chanda SK & Caldwell JS (2003) Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today 8: 168-174.
6. De Lucca AJ & Walsh TJ (1999) Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 43: 1-11.
7. Fuji K, Fujita E, Takaishi Y, Fujita T, Arita I, Komatsu M & Hiratsuka N (1978) New antibiotics, trichopolyns A and B: isolation and biological activity. Experientia 34: 237-239.
8. Goodnow RA Jr (2001) Current practices in generation of small molecule new leads. J Cell Biochem Suppl suppl. 37: 13-21.
9. Grollman AP (1967) Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J Biol Chem 242: 3226-3233.
10. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M & Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172- 1177.
11. Gura T (2000) A chemistry set for life. Nature 407: 282-284. Kadosh D & Lopez-Ribot JL (2013) Candida albicans: adapting to succeed. Cell Host Microbe 14: 483-485.
12. Kadosh D & Lopez-Ribot JL (2013) Candida albicans: adapting to succeed. Cell Host Microbe 14: 483-485
13. Klebe G (1994) Recent developments in structure-based drug design. J Mol Med 78: 269-281.
14. Kojic EM & Darouiche RO (2004) Candida infections of medical devices. Clin Microbiol Rev 17: 255-267.
15. Kucharikova S, Tournu H, Lagrou K, Van Dijck P & Bujdakova H (2011) Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. J Med Microbiol 60: 1261-1269.
16. Kucharikova S, Sharma N, Spriet I, Maertens J, Van Dijck P & Lagrou K (2013) Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model. Antimicrob Agents Chemother 57: 2365-2368.
17. Kuhn DM, George T, Chandra J, Mukherjee PK & Ghannoum MA (2002) Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46: 1773-1780.
18. Lemini C, Rubio-Poo C, Silva G, Garcia-Mondragon J, Zavala E, Mendoza-Patino N, Castro D, Cruz-Almanza R & Mandoki JJ (1993) Anticoagulant and estrogenic effects of two new 17 beta-aminoestrogens, butolame [17 beta-(4-hydroxy-1-butylamino)-1,3,5(10)-estratrien- 3-ol] and pentolame [17 beta-(5-hydroxy-1-pentylamino)-1,3,5 (10)-estratrien-3-ol]. Steroids 58: 457-461.
19. Lopez-Ribot JL (2005) Candida albicans biofilms: more than filamentation. Curr Biol 15: R453-R455.
20. Mathe L & Van Dijck P (2013) Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet 59: 251- 264.
21. Nett J & Andes D (2006) Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol 9: 340-345.
22. Nishimura H, Katagiri K, Sato K, Mayama M & Shimaoka N (1956) Toyocamycin, a new anti-candida antibiotics. J Antibiot (Tokyo) 9: 60-62.
23. Nobile CJ & Mitchell AP (2006) Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 8: 1382-1391.
24. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, Tuch BB, Andes DR & Johnson AD (2012) A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148: 126-138.
25. Pappas PG, Rex JH, Lee J et al. (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37: 634-643.
26. Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
27. Pierce CG & Lopez-Ribot JL (2013) Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov 8: 1117-1126.
28. Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr, Mowat E, Ramage G & Lopez-Ribot JL (2008) A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 3: 1494-1500.
29. Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK & Lopez-Ribot JL (2013) Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol 13: 726-730.
30. Ramage G, Vande Walle K, Wickes BL & Lopez-Ribot JL (2001) Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45: 2475-2479.
31. Ramage G, VandeWalle K, Lopez-Ribot JL & Wickes BL (2002) The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 214: 95-100.
32. Ramage G, Martinez JP & Lopez-Ribot JL (2006) Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 6: 979-986.
33. Ramage G, Mowat E, Jones B, Williams C & Lopez-Ribot J (2009) Our current understanding of fungal biofilms. Crit Rev Microbiol 35: 340-355.
34. Ruckdeschel G & Renner G (1986) Effects of pentachlorophenol and some of its known and possible metabolites on fungi. Appl Environ Microbiol 51: 1370-1372.
35. Saville SP, Lazzell AL, Monteagudo C & Lopez-Ribot JL (2003) Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2: 1053-1060.
36. Saville SP, Thomas DP & Lopez-Ribot JL (2005) Use of genome information for the study of the pathogenesis of fungal infections and the development of diagnostic tools. Rev Iberoam Micol 22: 238-241.
37. Shepherd MG, Ghazali HM & Sullivan PA (1980) N-acetyl-D-glucosamine kinase and germ-tube formation in Candida albicans. Exp Mycol 4: 147-159.
38. Tanaka H, Marumo H, Nagai T, Okada M, Taniguchi K & Omura S (1975) Nanaomycins, new antibiotics produced by a strain of Streptomyces. J Antibiot (Tokyo) 28: 925-930.
39. Vezina C, Kudelski A & Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28: 721-726.
40. Watanabe H, Azuma M, Igarashi K & Ooshima H (2005) Valinomycin affects the morphology of Candida albicans. J Antibiot (Tokyo) 58: 753-758.